prolonged progression-free survival amyloidosis is associated with high clonal response rates and Cyclophosphamide, bortezomib, and dexamethasone therapy in AL

[1]  F. Jardin,et al.  Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study , 2011, Haematologica.

[2]  D. Esseltine,et al.  Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. , 2011, Blood.

[3]  H. van de Velde,et al.  Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. , 2011, QJM : monthly journal of the Association of Physicians.

[4]  E. Riedel,et al.  Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[5]  P. Hawkins,et al.  Outcome in renal Al amyloidosis after chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Drach,et al.  Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis , 2011, Annals of Hematology.

[7]  D. Dingli,et al.  Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report , 2010, Leukemia & lymphoma.

[8]  P. L. Bergsagel,et al.  The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis , 2010 .

[9]  P. Cascio,et al.  Assessing Proteostasis and Proteasome Stress In Light Chain Amyloidosis , 2010 .

[10]  A. Foli,et al.  The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis , 2010 .

[11]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Dimopoulos,et al.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Morimoto,et al.  A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. , 2010, Current opinion in structural biology.

[14]  G. Salles,et al.  Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. , 2009, Blood.

[15]  P. Hawkins,et al.  In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment. , 2009 .

[16]  D. Reece,et al.  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.

[17]  P. L. Bergsagel,et al.  Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial , 2009, Leukemia.

[18]  P. Hawkins,et al.  Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease , 2008, Haematologica.

[19]  P. Hawkins,et al.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. , 2007, Blood.

[20]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[21]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.